Open access
Sep 2026
Safety of eribulin: A real-world study based on a pharmacovigilance database
Eribulin is used to treat metastatic breast cancer, but its adverse event (AE) profile requires comprehensive analysis using FDA Adverse Event Reporting System (FAERS) data to guide clinical use. We analyzed eribulin-related AE reports in FAERS (Q1 2011 - Q2 2024). Disproportionality analyses (ROR, PRR, MGPS, BCPNN) id...
Yao Zhou, Jie Gong, Le-Le Shen et al.
· PLoS ONE · 0 citations